Franklin Genomic Advancement Fund (HELX) at a glance
Franklin Genomic Advancement Fund (HELX) is a ETF company. It trades at $35.45. It does not pay a dividend. Vestovix scores it 52/100 overall. Its strongest dimension is Momentum (69/100) and its weakest is Income (40/100).
- Price
- $35.45
- Market cap
- n/a
- P/E ratio
- n/a
- Dividend yield
- None
- Beta
- n/a
- 52-week range
- $26.90 to $38.17
Value
50
Growth
50
Income
40
Safety
60
Momentum
69
Other ETF stocks
See all00883B.XTAI52
CTBC 15+ Year Developed Markets US Corporate Best-in-Class ESG Bond ETF
NT$30.98+0.00%
EMMVN.MX54
iShares Edge MSCI EM Minimum Volatility UCITS ETF
MX$760.43+5.93%
ESIX53
SPDR S&P SmallCap 600 ESG ETF
$34.76+0.00%
GGPY.F.NEOE--
Guardian Directed Premium Yield Portfolio Series A
CA$16.55+2.29%
GIUS.F.NEOE--
Guardian i³ U.S. Core Equity Fund
CA$40.65+0.25%
GUTB.U.NEOE--
Guardian Capital L.P.
$50.04+0.02%
HBF.B.NEOE--
Harvest Brand Leaders Plus Income Fund
CA$13.46+1.28%
HBF.U.NEOE--
Harvest Brand Leaders Plus Income ETF
$13.32+0.08%